0001104659-22-075659.txt : 20220802 0001104659-22-075659.hdr.sgml : 20220802 20220629120759 ACCESSION NUMBER: 0001104659-22-075659 CONFORMED SUBMISSION TYPE: CORRESP PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20220629 FILER: COMPANY DATA: COMPANY CONFORMED NAME: AGILE THERAPEUTICS INC CENTRAL INDEX KEY: 0001261249 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: CORRESP BUSINESS ADDRESS: STREET 1: 500 COLLEGE ROAD EAST STREET 2: SUITE 310 CITY: PRINCETON STATE: NJ ZIP: 08540-6635 BUSINESS PHONE: 609-683-1880 MAIL ADDRESS: STREET 1: 500 COLLEGE ROAD EAST STREET 2: SUITE 310 CITY: PRINCETON STATE: NJ ZIP: 08540-6635 CORRESP 1 filename1.htm

 

 

June 29, 2022

 

VIA FACSIMILE AND EDGAR

 

U.S. Securities and Exchange Commission

Division of Corporate Finance

Washington, DC 20549

 

Re:Agile Therapeutics, Inc.
  Registration Statement on Form S-1 (Registration No. 333-264960)
  Concurrence in Acceleration Request

 

Ladies and Gentlemen:

 

H.C. Wainwright & Co., LLC (“Wainwright”), solely acting as placement agent on a best efforts basis in an offering pursuant to the registration statement on Form S-1 (333-264960) (the “Registration Statement”), hereby concurs in the request by Agile Therapeutics, Inc. that the effective date of the above-referenced registration statement be accelerated to 9:00 A.M. (Eastern Time), or as soon as practicable thereafter, on July 1, 2022, pursuant to Rule 461 under the Securities Act. Wainwright affirms that it is aware of its obligations under the Securities Act as they pertain to the best efforts offering pursuant to the Registration Statement.

 

 

 

 

Securities and Exchange Commission
June 29, 2022
Page 2

 

Very truly yours,
   
 H.C. WAINWRIGHT & CO., LLC
   
 By:/s/ Edward D. Silvera
     Name: Edward D. Silvera
     Title: Chief Operating Officer